Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

NCT05894343 · tracked via the Priya Life Science USA tracker

Sponsor

MeiraGTx, LLC

Phase

Phase 1/2

Started

2023-05-19

Last updated

2026-09-01

Condition(s) studied

Parkinson's Disease

Investigational drug(s) / intervention(s)

AAV-GAD

AAV-GAD: Bilateral infusion of AAV-GAD

Study summary

The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.

Eligibility

Sex

ALL

Min age

25 Years

Max age

86 Years

Healthy volunteers

Inclusion Criteria: * Previously enrolled in Study MGT-GAD-025. Exclusion Criteria: * None

Primary outcome measure(s)

Number of participants with study drug-related adverse events and serious adverse events — From study start until Month 60 post treatment

Trial sites (6)

Facility	City	Region
Yale University	New Haven	Connecticut
Henry Ford West Bloomfield Hospital	West Bloomfield	Michigan
Weill Cornell Medicine	New York	New York
Columbia University Irving Medical Center	New York	New York
Thomas Jefferson University	Philadelphia	Pennsylvania
West Virginia University	Morgantown	West Virginia

More MeiraGTx, LLC trials in the USA

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia Active, not recruiting

Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia Active, not recruiting

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia Enrolling by invitation

Other trials for the same condition

A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations Recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease Recruiting

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease Active, not recruiting

AB-1005 Long-Term Follow-up Study Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05894343 on ClinicalTrials.gov ↗ ← All trials in the USA